Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

11.39 10.48

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.77

Max

11.41

Pagrindiniai rodikliai

By Trading Economics

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+46.85% upside

Naujienos nuotaikos

By Acuity

100%

0%

329 / 342 reitingas Healthcare

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-02 23:41; UTC

News
Social Media

Meta shares rise in after-market trading as CEO Zuckerberg highlights upcoming AI benefits and announces new application Pocket, despite some setbacks.

2026-07-02 23:32; UTC

News
Social Media

Microsoft launches AI initiative Microsoft Frontier Company with $2.5 billion backing. Shares are higher in after-market trading, continuing the broader software sector's upward trend.

2026-07-02 23:31; UTC

News
Social Media
ETF Constituents
Correlated Moves

The Nasdaq 100 Index is higher in after-market hours, buoyed by U.S. jobless data and positive contributions from Microsoft, Meta, and Texas Instruments.

2026-07-02 23:26; UTC

News

O'Reilly Automotive's $10 billion bid for Genuine Parts' division coincides with a decline in shares during after-market trading. Genuine Parts' shares rose significantly.

2026-07-02 23:26; UTC

News

Qualcomm shares are higher in after-market hours despite Elon Musk's denial of a partnership with SpaceX and removal from Russell indexes.

2026-07-02 23:16; UTC

Correlated Moves
News
Macro News
ETF Constituents

Vanguard Information Technology ETF gains after-hours, supported by positive contributions from Microsoft and Texas Instruments, following favorable U.S. jobless data.

2026-07-02 23:16; UTC

News

Microchip Technology Inc shares are higher in after-market trading, despite concerns over AI-driven chip demand and a recent pullback in the Philadelphia Semiconductor Index.

2026-07-02 23:12; UTC

News

Applied Materials shares advanced in after-hours trading, buoyed by positive equity market sentiment and gains in European indices like the DAX.

2026-07-02 23:11; UTC

News
Macro Event
Correlated Moves

The USD/CZK exchange rate is lower today, reflecting recent U.S. labor market data and broader market sentiment influencing currency movements.

2026-07-02 23:11; UTC

Macro Event
News

The USD/PLN exchange rate is lower today, reflecting a decline since Wednesday's close amid mixed U.S. labor market data and unusual volatility.

2026-07-02 23:11; UTC

News
Social Media
Correlated Moves

The EUR/HKD exchange rate is rising, supported by U.S. Dollar weakness after disappointing nonfarm payroll data and positive GBP/USD movements.

2026-07-02 23:11; UTC

News
Macro Event

The U.S. Dollar weakened against the Danish Krone following disappointing June nonfarm payroll data, which showed only 57,000 jobs added.

2026-07-02 23:11; UTC

News
Social Media
Correlated Moves

Weakness in the U.S. Dollar, following disappointing payroll data, supports gains in GBP/HKD during Thursday's session. The asset is higher since Wednesday's close.

2026-07-02 23:11; UTC

News
Macro Event
Correlated Moves

The USD/NOK exchange rate is lower, influenced by weaker U.S. job growth and correlated declines in USD/CAD. Volatility remains notable during Thursday's session.

2026-07-02 23:11; UTC

Correlated Moves
News

Bitcoin remains higher despite SBI Crypto's cessation of mining operations. Earlier in the session, it pulled back from a peak amid significant volatility.

2026-07-02 23:06; UTC

News

Amgen Inc shares declined in after-market trading despite a favorable court ruling blocking a proposed price cap on its drug Enbrel.

2026-07-02 23:06; UTC

Correlated Moves
News

Gold trades slightly higher in after-market hours, supported by a modest rise in silver and tempered rate hike expectations following a weaker jobs report.

2026-07-02 23:01; UTC

Macro Event
News

The USD/ZAR exchange rate is lower today, impacted by weaker U.S. Non-Farm Payrolls data revealing only 57,000 jobs added in June.

2026-07-02 22:51; UTC

Macro Event
News

The Nikkei 225 Index declined in after-market hours, pressured by a sell-off in semiconductor shares and strengthened yen amid government intervention expectations.

2026-07-02 20:13; UTC

ETF Constituents
News

Vanguard Large-Cap ETF declines after market close, influenced by broader market conditions and weaker U.S. jobs data. Holdings like Google and Johnson & Johnson also posted losses.

2026-07-02 20:13; UTC

News
Correlated Moves

The Japanese yen strengthened to a two-week high against the U.S. dollar amid global uncertainties, while Invesco Currencyshares Japanese Yen Trust is trading roughly flat after hours.

2026-07-02 20:07; UTC

Correlated Moves
News
Macro Event

The USD/HUF exchange rate is declining amid disappointing US job growth and a weaker US Dollar Index, with notable intraday volatility.

2026-07-02 20:06; UTC

News

Liberty Global shares are higher as Liberty Latin America is added to several Russell Growth indices, potentially boosting visibility to passive funds and investors.

2026-07-02 20:06; UTC

Correlated Moves
News
Macro Event

The USD/SGD exchange rate is lower today, reflecting pressure from weaker U.S. job growth data and a declining U.S. Dollar Index.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices rise amid weaker U.S. jobs data, which reported only 57,000 new jobs. Easing oil prices and rising silver also support gold's appeal.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher today, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:06; UTC

News
Correlated Moves

Gold prices are higher, supported by weaker U.S. jobs data and easing oil prices. Silver's rise also contributes to gold's appeal as a safe haven.

2026-07-02 20:05; UTC

Correlated Moves
Social Media
ETF Constituents
News

The Communication Services Select Sector SPDR Fund is underperforming, reflecting a decline in the Communications sector. The fund remains roughly flat since Wednesday's close.

2026-07-02 20:05; UTC

News
Social Media

Tesla Inc's stock is declining amid profit-taking despite strong delivery figures. Analysts raised the price target to $430, but investor concerns persist.

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

46.85% į viršų

12 mėnesių prognozė

Vidutinis 16.8 USD  46.85%

Aukščiausias 20 USD

Žemiausias 13.6 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat